Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

Dicerna Pharmaceuticals In Form 4 January 05, 2017	nc						
FORM 4						PPROVAL	
UNITE	D STATES	SECURITIES AN Washington,		NGE COMMISSION	OMB Number:	3235-0287	
Section 16. Form 4 or Form 5 Filed J obligations Section	pursuant to S	CHANGES IN F SECUR Section 16(a) of the Public Utility Hold	Expires:January 31, 2005Estimated average burden hours per response0.5				
may continue. Section 5 See Instruction 1(b).		of the Investment (· · ·				
(Print or Type Responses)							
1. Name and Address of Report Brown Bob D	2. Issuer Name and Symbol Dicerna Pharmace [DRNA]		Issuer	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) C/O DICERNA PHARMACEUTICALS, I CAMBRIDGEPARK DR	3. Date of Earliest Tra (Month/Day/Year) 01/03/2017	below)			e title 10% Owner other (specify below) Scientific Officer		
(Street) CAMBRIDGE, MA 0214)	Filed(Month/Day/Year) Ap			dual or Joint/Group Filing(Check le Line) n filed by One Reporting Person n filed by More than One Reporting		
				Person			
(City) (State)	(Zip)	Table I - Non-Do	erivative Secur	ities Acquired, Disposed of	, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)2. Transaction D (Month/Day/Yea)		Date, if Transaction Code I	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5 (A) or Amount (D)	Securities F Beneficially (1 5) Owned (1	Form: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on a separate	line for each cla		. ,				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration I (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (E) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Employee Stock Option (Right to Buy	\$ 2.97	01/03/2017		A	75,000	<u>(1)</u>	01/03/2027	Common Stock	75,000	

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Brown Bob D C/O DICERNA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140			Chief Scientific Officer		
Signatures					

/s/ John B. Green, attorney-in-fact 01/05/2017

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.